Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain ...

Formosa Pharmaceuticals and Cipla Limited have entered into an exclusive licensing agreement for the commercialization of ...

Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain ...

Drug maker Cipla on Tuesday said it has inked an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals for the commercialisation of clobetasol propionate ophthalmic suspension. As ...

Taiwan-based Formosa Pharmaceuticals (6838.TW) today announced an exclusive licensing agreement with Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as "Cipla" for the commercialization of ...

This new steroid represents a significant advancement in the ophthalmic market, extending notable patient benefits, the company stated.

Combination, if successful, would create a new publicly-listed eye care company combining Betaliq’s EyeSol® water-free drug delivery technology ...

Cipla has announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals to market clobetasol ...

The company’s current commercial portfolio includes clobetasol propionate ophthalmic suspension, 0.05%, for post-surgical pain and inflammation, and Mydcombi® for mydriasis. For more ...

Sofinnova Partners, a leading European life sciences venture capital firm, in collaboration with Gustave Roussy, Europe's leading cancer center, announces the creation of their first pioneering ...